Fig. 2: Exploratory subgroup analyses of pCR by baseline factors. | Nature Communications

Fig. 2: Exploratory subgroup analyses of pCR by baseline factors.

From: A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer

Fig. 2

Data are presented as pCR rate (%) and 95% CI. The black squares indicate the pCR rates following stratifications. pCR pathological complete response, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, FISH fluorescence in situ hybridization, ER estrogen receptor, PR progesterone receptor, CI confidence interval. Source data are provided as a Source Data file.

Back to article page